Dr. Mezgebe Berhe discusses Baylor Scott & White's participation in the Regeneron trial and how it could benefit the President of the United States
The eyes of the world are on the latest patient to be diagnosed with COVID-19: President Donald Trump. According to reports, President Trump has just received antibodies from Regeneron in an effort to help his body fight off the illness.
Baylor Scott & White Research Institute in Dallas was the first in the country to enroll a patient in the study of the antibody developed by Regeneron back in June 2020.
The physician researcher who is leading this trial in Dallas, Mezgebe Berhe, MD, is available for interviews this evening.
We also just recorded an on-camera interview that you are welcome to use in forming a story:
https://vimeo.com/464394952/26d8f58933
Here are some quotes from Dr. Berhe (pronounced “burr-hey”). He is an infectious disease physician at Baylor University Medical Center.
“Through this trial, we hope to learn more about if these monoclonal antibodies can prevent the progression of this disease and help save lives.”
“By preventing the virus from attaching to other cells in the body, we are essentially shutting down viral replication. For this reason, they’re called neutralizing antibodies.”
Background
While a number of clinical trials are composed of medications intended for other conditions, this trial uses specific monoclonal antibodies, also known as anti-spike antibodies, to bind to the spike protein of the COVID-19 virus, and prevent it from attaching to human cells.
Baylor Scott & White was the first Texas health system approved to conduct a number of industry-sponsored trials, including remdesivir trials for moderate and severe patients, as well as the first outpatient antibody clinical trial led by Eli Lilly and Company and the first monoclonal antibodies study led by Regeneron.
Learn more about Baylor Scott & White’s participation in the Regeneron Trial click: Antibodies: What are they and how are they used in COVID-19 research and treatment?
For patients diagnosed and interested in learning more
Patients in the DFW area who have tested positive for COVID-19 may call Baylor Scott & White Research Institute to learn more about this and other available COVID-19-related research trials:
1-888-50-RESEARCH
About Baylor Scott & White Research Institute
Extending investigational expertise across more than 50 specialties areas, Baylor Scott & White Research Institute provides the business and regulatory infrastructure to accelerate medical breakthroughs and innovative new treatment models through clinical and translational activities. Baylor Scott & White Research Institute is present at sites and centers across Baylor Scott & White Health and maintains nearly 2,000 active trials each year.
About Baylor Scott & White Health
As the largest not-for-profit health system in the state of Texas, Baylor Scott & White Health promotes the health and well-being of every individual, family and community it serves. An integrated care delivery network, the system includes the Scott and White Health Plan, Baylor Scott & White Research Institute and Baylor Scott & White Quality Alliance. Through 52 hospitals and more than 1,100 access points including flagship academic medical centers in Dallas and Temple, the system offers the full continuum of care, from primary to award-winning specialty care, throughout Texas, and via virtual touchpoints. If its service area were a state, it would be the eighth largest, providing care to a population larger than that of the state of Georgia. Founded as a Christian ministry of healing, Baylor Scott & White is proud to honor its century-long legacy through its commitment to improving accessibility, affordability and the customer experience for all. For more information, visit
RSS